62.475 USD
-0.41 (-0.64%)
HALO gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. HALO scores excellent on profitability, but there are some minor concerns on its financial health. An interesting combination arises when we look at growth and value: HALO is growing strongly while it also seems undervalued. These ratings would make HALO suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
HALO had positive earnings in the past year.
In the past year HALO had a positive cash flow from operations.
Each year in the past 5 years HALO has been profitable.
Each year in the past 5 years HALO had a positive operating cash flow.
1.2 Ratios
HALO has a Return On Assets of 26.81%. This is amongst the best in the industry. HALO outperforms 97.55% of its industry peers.
The Return On Equity of HALO (118.17%) is better than 99.62% of its industry peers.
The Return On Invested Capital of HALO (42.77%) is better than 99.25% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 18.22%.
The last Return On Invested Capital (42.77%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
The Profit Margin of HALO (47.91%) is better than 98.12% of its industry peers.
HALO's Profit Margin has declined in the last couple of years.
HALO has a Operating Margin of 59.33%. This is amongst the best in the industry. HALO outperforms 99.81% of its industry peers.
HALO's Operating Margin has declined in the last couple of years.
The Gross Margin of HALO (84.55%) is better than 87.01% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, HALO has less shares outstanding
HALO has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, HALO has an improved debt to assets ratio.
2.2 Solvency
HALO has an Altman-Z score of 4.82. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.82, HALO is doing good in the industry, outperforming 72.32% of the companies in the same industry.
HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
The Debt to FCF ratio of HALO (2.51) is better than 93.22% of its industry peers.
A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.59, HALO is doing worse than 79.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 4.82 |
ROIC/WACC5.49
WACC7.79%
2.3 Liquidity
A Current Ratio of 1.59 indicates that HALO should not have too much problems paying its short term obligations.
HALO's Current ratio of 1.59 is on the low side compared to the rest of the industry. HALO is outperformed by 81.73% of its industry peers.
HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
HALO has a Quick ratio of 1.37. This is amonst the worse of the industry: HALO underperforms 83.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.55% over the past year.
Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.12% on average per year.
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 31.19%.
HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.95% yearly.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
Based on estimates for the next years, HALO will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.25% on average per year.
The Revenue is expected to grow by 12.82% on average over the next years. This is quite good.
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y31.96%
EPS Next 5Y17.25%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.56%
Revenue Next 5Y12.82%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.10, which indicates a very decent valuation of HALO.
Based on the Price/Earnings ratio, HALO is valued cheaper than 97.18% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.34. HALO is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 7.53, the valuation of HALO can be described as very cheap.
Based on the Price/Forward Earnings ratio, HALO is valued cheaply inside the industry as 99.44% of the companies are valued more expensively.
HALO is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.1 | ||
| Fwd PE | 7.53 |
4.2 Price Multiples
96.99% of the companies in the same industry are more expensive than HALO, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 97.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.2 | ||
| EV/EBITDA | 9.67 |
4.3 Compensation for Growth
HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
HALO's earnings are expected to grow with 31.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y40.02%
EPS Next 3Y31.96%
5. Dividend
5.1 Amount
No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HALO (12/9/2025, 11:55:49 AM)
62.475
-0.41 (-0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.69%
Inst Owner Change15.59%
Ins Owners0.83%
Ins Owner Change-0.62%
Market Cap7.35B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts77.33
Price Target77.52 (24.08%)
Short Float %10.74%
Short Ratio5.58
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)0.44%
PT rev (3m)6.29%
EPS NQ rev (1m)-0.62%
EPS NQ rev (3m)1.57%
EPS NY rev (1m)1.91%
EPS NY rev (3m)2.25%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)0.56%
Revenue NY rev (1m)1.78%
Revenue NY rev (3m)1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.1 | ||
| Fwd PE | 7.53 | ||
| P/S | 5.91 | ||
| P/FCF | 12.2 | ||
| P/OCF | 12.02 | ||
| P/B | 14.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.67 |
EPS(TTM)5.63
EY9.01%
EPS(NY)8.29
Fwd EY13.27%
FCF(TTM)5.12
FCFY8.2%
OCF(TTM)5.2
OCFY8.32%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.22
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 4.82 |
F-Score8
WACC7.79%
ROIC/WACC5.49
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y31.96%
EPS Next 5Y17.25%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.56%
Revenue Next 5Y12.82%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.25%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 10 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 11.1 and the Price/Book (PB) ratio is 14.58.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.